Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT07371897 2026-01-28

SHINE

Phase 3 Not yet recruiting

154 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05635643 2025-08-01

Study of CHS-114 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT07088211 2025-07-31

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Phase 2 Recruiting

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

Phase 2 Not yet recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06378177 2024-06-27

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Recruiting

64 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05773079 2024-04-01

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Unknown

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05993858 2023-08-15

PC-1

Phase 2 Not yet recruiting

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Phase 2 Recruiting

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Phase 2 Unknown

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04947241 2021-07-01

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04523883 2021-04-15

IMPORT

Phase 2 Unknown

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04164238 2019-11-15

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Phase 2 Unknown

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

SHINE

Study of CHS-114 in Participants With Advanced Solid Tumors

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

PC-1

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

IMPORT

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients